GlobeNewswire
Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
📊
AI Sentiment
Positive
6/10
- Home
- TNGX
as of 02-06-2026 4:00pm EST
$12.51
+$0.56
+4.69%
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 1.4B | IPO Year: | N/A |
| Target Price: | $13.00 | AVG Volume (30 days): | 3.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.91 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.03 - $13.46 | Next Earning Date: | 02-26-2026 |
| Revenue: | $66,501,000 | Revenue Growth: | 53.29% |
| Revenue Growth (this year): | 52.8% | Revenue Growth (next year): | -82.18% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -146765000.0 | FCF Growth: | N/A |
AI-Powered TNGX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 72.55%
72.55%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Tango Therapeutics Inc. (TNGX)
Weber Barbara
Sell
Director, Executive Chair
TNGX Feb 3, 2026
Avg Cost/Share
$12.58
Shares
30,519
Total Value
$374,293.59
Owned After
1,629,587
Beckman Daniella
Sell
Chief Financial Officer
TNGX Feb 3, 2026
Avg Cost/Share
$12.58
Shares
10,317
Total Value
$126,530.86
Owned After
184,410
Crystal Adam
Sell
President, R&D
TNGX Feb 3, 2026
Avg Cost/Share
$12.58
Shares
18,452
Total Value
$226,300.30
Owned After
187,419
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Weber Barbara | TNGX | Director, Executive Chair | Feb 3, 2026 | Sell | $12.58 | 30,519 | $374,293.59 | 1,629,587 | |
| Beckman Daniella | TNGX | Chief Financial Officer | Feb 3, 2026 | Sell | $12.58 | 10,317 | $126,530.86 | 184,410 | |
| Crystal Adam | TNGX | President, R&D | Feb 3, 2026 | Sell | $12.58 | 18,452 | $226,300.30 | 187,419 |
Latest Tango Therapeutics Inc. News
TNGX Breaking Stock News: Dive into TNGX Ticker-Specific Updates for Smart Investing
Compare TNGX vs Leading Stocks
See how TNGX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "TNGX Tango Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.